Holen Sie sich die Stockscreener-App
89.17
2.28%
-2.08
Handel nachbörslich:
89.12
-0.05
-0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$91.25
Offen:
$91.32
24-Stunden-Volumen:
11.89M
Relative Volume:
0.94
Marktkapitalisierung:
$155.32B
Einnahmen:
$45.13B
Nettoeinkommen (Verlust:
$6.28B
KGV:
24.84
EPS:
3.5895
Netto-Cashflow:
$7.38B
1W Leistung:
+2.51%
1M Leistung:
+5.75%
6M Leistung:
-27.24%
1J Leistung:
-33.52%
1-Tages-Spanne:
$88.69
$91.32
1-Wochen-Bereich:
$88.69
$92.73
52-Wochen-Spanne:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
89.17 | 158.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.84 | 120.38B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.25 | 105.25B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.34 | 72.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.98 | 50.41B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness - Yahoo Finance
Abbott office in Easton part of multi-state portfolio sale - The Business Journals
Abbott Laboratories Hit With Lawsuit Over Healthcare Plan Costs - Bloomberg Law News
Abbott Defeats Account Manager’s Sexualized Workplace Claim - Bloomberg Law News
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story - Yahoo Finance
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
BSX, MDT Top Abbott Laboratories Stock on Price & Potential - Trefis
Abbott Laboratories: A Better Than 5 Years AgoBut Still Not A Buy - Seeking Alpha
3 Large Cap Defensive Dividend Stocks With Underestimated Payout Power - simplywall.st
Abbott (ABT) Secures CE Mark for World’s First Dual Glucose‑Ketone Sensing Technology for Diabetes - Insider Monkey
Abbott Laboratories stock (US0028241000): New filing, modest gain, and valuation focus - AD HOC NEWS
Abbott Laboratories stock (US0028241000): analysts stay positive as new diabetes data and steady gai - AD HOC NEWS
Abbott Laboratories price gives in to negative pressureForecast today09-06-2026 - Economies.com
ABT DCF Analysis: Intrinsic Value $93 vs Price $90 - GuruFocus
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109 - Moomoo
Richard W. Allen Sells Shares in Abbott Laboratories, Ameriprise Financial and More - Investing.com Nigeria
Similac baby formula maker sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com
Abbott Laboratories, maker of Similac baby formula, sued by Allegheny County parents over infant’s 2011 death - TribLIVE.com
Governor Abbott, Secretary Rollins Update Texans On Screwworm Response At Kerrville Lab - Office of the Texas Governor (.gov)
Abbott's Healthy Food Rx Program Shows Promising Results for Dia - GuruFocus
Is It Time To Revisit Abbott Laboratories (ABT) After This Year’s Share Price Slump? - Yahoo Finance
Can Beyond Meat's Pivot to Protein Drinks Change the Investment Thesis? - The Motley Fool
Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock - Insider Monkey
LIVE: Abbott activates emergency center for screwworm response, USDA says 2 more Texas cases - KLBK
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $120 - 富途牛牛
Abbott activates emergency center for screwworm response, USDA says 2 more Texas cases - KXAN Austin
Food boxes and coaches tied to better diabetes health, less food insecurity - Stock Titan
Abbott Laboratories (ABT) Up 6.4% Following European CE Mark Approval of Dual Glucose-Ketone Sensors - Meyka
Abbott Buy Rating Reaffirmed as Analyst Sees Accelerating 2027 Earnings; $120 Price Target Maintained on Libre Duo Growth Potential - TipRanks
Abbott Laboratories (ABT) Investor Outlook: Harnessing A 28.79% Potential Upside - DirectorsTalk Interviews
Abbott (ABT) Highlights Dangers of Diabetic Ketoacidosis in New Research Findings - GuruFocus
Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors - simplywall.st
Abbott studies reinforce DKA opportunity following dual sensor milestone - Drug Delivery Business
Abbott reports rising DKA hospitalizations among diabetics - Investing.com
Kids’ diabetes hospital stays now mostly from ketoacidosis, Abbott finds - Stock Titan
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
ABT Stock Quote Price and Forecast - CNN
Abbott Says Timing Mismatch Lets $8B Gain Go Untaxed - Law360
What is Abbott Tokenized Stock (Ondo)(ABTON) Coin? A comprehensive guide you shouldn’t miss - WEEX
A Grandma Bought PediaSure To Help Her Grandson Grow — Now, Abbott Is In Federal Court - Benzinga
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Is It Too Late to Buy Abbott Laboratories (ABT) After 4.4% Rally? GF Value Says Undervalued - GuruFocus
Judge Questions Fees In Abbott Investors' $40M Formula Deal - Law360
Abbott Can’t Drop PediaSure Children’s Growth Deception Suit - Bloomberg Law News
Abbott Labs must face lawsuit over PediaSure children's growth claims - Reuters
Abbott Labs must face lawsuit over PediaSure children’s growth claims - The Mighty 790 KFGO
Abbott Laboratories Stock (ABT) Closed Up by 4.18% on Jun 4: Drivers Behind the Movement - TradingKey
Abbott Laboratories stock (US0028241000): shares advance on strong US trading - AD HOC NEWS
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
Abbott Laboratories stock gains as Norges Bank acquires new institutional position - Traders Union
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):